Vincristine
| Evidence Level: L3 | Predicted Indications: 3 |
Table of Contents
- Vincristine
- Vincristine: From Hematologic Malignancies (Leukemia and Lymphoma) to Ganglioneuroblastoma
Vincristine: From Hematologic Malignancies (Leukemia and Lymphoma) to Ganglioneuroblastoma
One-Sentence Summary
Vincristine is a vinca alkaloid chemotherapy drug, originally used for acute lymphoblastic leukemia, Hodgkin and non-Hodgkin lymphoma, mantle cell lymphoma and Langerhans cell histiocytosis. The TxGNN model predicts it may be effective for ganglioneuroblastoma, but there are currently no registered clinical trials and only 6 publications (mostly case reports) supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acute lymphoblastic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma and related lymphomas (from the knowledge graph; New Zealand licence entries contain no indication text) |
| Predicted New Indication | Ganglioneuroblastoma |
| TxGNN Prediction Score | 99.31% |
| Evidence Level | L3 |
| New Zealand Market Status | Cancelled only (no currently valid licence) |
| Number of Authorizations | 3 (all cancelled) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, vincristine is a vinca alkaloid that binds tubulin and inhibits microtubule polymerization, causing mitotic arrest in rapidly dividing cells.
Ganglioneuroblastoma belongs to the neuroblastic tumor spectrum. In this family, vincristine is a standard component of multi-agent chemotherapy regimens (for example with cyclophosphamide, doxorubicin and cisplatin). This is consistent with the high TxGNN score.
An important caveat: ganglioneuroblastoma is often treated with surgery alone. Chemotherapy is usually reserved for intermediate- or high-risk or unresectable disease. The evidence summarized here is based on publication titles and abstracts, and the specific regimens in each paper were not verified.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31342649 | 2019 | Prospective clinical trial | Pediatr Blood Cancer | JN-L-10 trial using image-defined risk factors to guide surgical timing in low-risk neuroblastoma; focus is surgery and risk stratification, not vincristine |
| 8255850 | 1993 | Case report | Postgrad Med J | Unresectable spinal ganglioneuroblastoma achieved histologically proven complete remission with chemotherapy alone (doxorubicin, vincristine, cyclophosphamide, etoposide, ifosfamide, cisplatin) |
| 15701990 | 2005 | Case report | J Pediatr Hematol Oncol | Ganglioneuroblastoma presenting with obstructive jaundice, treated with chemotherapy including cisplatin, pirarubicin/doxorubicin, cyclophosphamide and vincristine |
| 3071124 | 1988 | Case report | Hinyokika Kiyo | Multimodality treatment of adult adrenal ganglioneuroblastoma with large regional lymph node metastasis |
| 8888754 | 1996 | Case report | J Pediatr Hematol Oncol | Infant with stage 4 multifocal ganglioneuroblastoma with gastric involvement |
| 7421294 | 1980 | Case report | J Thorac Cardiovasc Surg | 31 patients with intrathoracic ganglioneuroblastoma treated with resection, radiation or chemotherapy; 27 survived, up to 25 years of follow-up |
New Zealand Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 2204053 | Baxter | Inj 1 mg for ECP | Not stated (cancelled) |
| 604593 | DBL Vincristine Sulfate | Inj 1 mg per ml, 2 ml vial | Not stated (cancelled) |
| 604585 | DBL Vincristine Sulfate | Inj 1 mg per ml, 1 ml vial | Not stated (cancelled) |
All three licences are cancelled, so there is currently no valid vincristine product on the New Zealand market.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (vinca alkaloid, antimicrotubule agent) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions (the knowledge graph lists leukopenia as a contraindicated condition) |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Complete blood count, liver function (including bilirubin), and neurological assessment for peripheral neuropathy |
| Handling Protection | Must follow cytotoxic drug handling regulations |
Safety Considerations
- Contraindicated conditions (from knowledge graph, not label text):
- Liver and biliary: liver failure, hyperbilirubinemia (including hereditary forms and Gilbert syndrome), cholestasis (including benign recurrent and familial intrahepatic forms)
- Nervous system: peripheral neuropathy and other peripheral nervous system disease, neuromuscular disease, Charcot-Marie-Tooth disease, motor neuropathy, neuritis
- Blood and metabolic: leukopenia, acute urate nephropathy
- Infections: infectious disease, fungal infection, dermatophytosis
- Drug Interactions: 505 interactions were recorded. Notable examples:
- Major: clarithromycin
- Moderate: aprepitant, dexamethasone, metronidazole, eliglustat, naltrexone, glycerol phenylbutyrate, miconazole, rolapitant, rosuvastatin, simvastatin, tinidazole, troglitazone
- Minor: levofloxacin
Package insert warnings and contraindications were not available. Please refer to the package insert for the full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The biological rationale is plausible, since vincristine is a known component of neuroblastic tumor regimens. However, the supporting evidence is limited to case reports and one surgery-focused trial, there are no registered clinical trials, and no valid New Zealand licence exists. Package insert safety data are also missing, so safety screening cannot proceed.
To proceed, the following is needed:
- Medsafe package insert warnings and contraindications (blocking gap)
- Mechanism of action data from DrugBank
- Review of the specific chemotherapy regimens and outcomes in the ganglioneuroblastoma publications
- Assessment of whether a vincristine product can be supplied in New Zealand, given that all licences are cancelled
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.